82 related articles for article (PubMed ID: 25707790)
1. Education and imaging. Hepatology: Complete regression of locally advanced hepatocellular carcinoma following Sorafenib monotherapy.
Kumar S
J Gastroenterol Hepatol; 2015 Mar; 30(3):438. PubMed ID: 25707790
[No Abstract] [Full Text] [Related]
2. Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma.
Maida M; Macaluso FS; Valenza F; Virdone R
J Gastrointestin Liver Dis; 2016 Jun; 25(2):253-5. PubMed ID: 27308660
[TBL] [Abstract][Full Text] [Related]
3. A complete response induced by 21-day sorafenib therapy in a patient with advanced hepatocellular carcinoma.
Hagihara A; Teranishi Y; Kawamura E; Fujii H; Iwai S; Morikawa H; Enomoto M; Tamori A; Kawada N
Intern Med; 2013; 52(14):1589-92. PubMed ID: 23857091
[TBL] [Abstract][Full Text] [Related]
4. Case of sorafenib-induced thyroid storm.
Haraldsdottir S; Li Q; Villalona-Calero MA; Olencki TE; Kendra K; Ing SW
J Clin Oncol; 2013 Jun; 31(16):e262-4. PubMed ID: 23610115
[No Abstract] [Full Text] [Related]
5. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
[TBL] [Abstract][Full Text] [Related]
6. Treatment Response After Unusual Low Dose Sorafenib: Diagnosis with Perfusion CT and Follow-up in a Patient with Recurrent Hepatocellular Carcinoma.
Sacco R; Faggioni L; Bargellini I; Romano A; Bertini M; Ginanni B; Battaglia V; Bertoni M; Bozzi E; Federici G; Metrangolo S; Parisi G; Neri E; Sodini E; Tumino E; Bresci G; Bartolozzi C
J Gastrointest Cancer; 2012 Sep; 43 Suppl 1():S234-8. PubMed ID: 22752423
[No Abstract] [Full Text] [Related]
7. Comparison of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study.
Shiozawa K; Watanabe M; Ikehara T; Kogame M; Matsui T; Okano N; Kikuchi Y; Nagai H; Ishii K; Makino H; Igarashi Y; Sumino Y
Hepatogastroenterology; 2014 Jun; 61(132):885-91. PubMed ID: 26158136
[TBL] [Abstract][Full Text] [Related]
8. Sustained remission over 36 months of advanced hepatocellular carcinoma after short-term sorafenib therapy.
Ahn SY; Lee HS; Kweon YO; Tak WY; Park SY
Dig Dis Sci; 2013 May; 58(5):1428-32. PubMed ID: 23306847
[No Abstract] [Full Text] [Related]
9. Combined Treatment of Tyrosine Kinase Inhibitor-Labeled Gold Nanorod Encapsulated Albumin With Laser Thermal Ablation in a Renal Cell Carcinoma Model.
Callaghan C; Peralta D; Liu J; Mandava SH; Maddox M; Dash S; Tarr MA; Lee BR
J Pharm Sci; 2016 Jan; 105(1):284-92. PubMed ID: 26852860
[TBL] [Abstract][Full Text] [Related]
10. The role of sorafenib in hepatocellular carcinoma.
Gholam P
Clin Adv Hematol Oncol; 2015 Apr; 13(4):232-4. PubMed ID: 26352581
[No Abstract] [Full Text] [Related]
11. Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib.
Brandi G; De Lorenzo S; Di Girolamo S; Bellentani S; Saccoccio G; Biasco G
Tumori; 2015 Apr; 101(2):e46-8. PubMed ID: 25702656
[TBL] [Abstract][Full Text] [Related]
12. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
[No Abstract] [Full Text] [Related]
13. Durable spontaneous regression of lung metastases from renal cell carcinoma after incomplete use of multiple kinase inhibitor sorafenib.
Hegde U; Patel V; Kaloudis E
Int J Urol; 2013 Jun; 20(6):644-5. PubMed ID: 23186003
[No Abstract] [Full Text] [Related]
14. New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma.
Galmiche A; Chauffert B; Barbare JC
Cancer Lett; 2014 May; 346(2):159-62. PubMed ID: 24380851
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
İlknur T; Akarsu S; Çarsanbali S; Lebe B; Fetil E
J Drugs Dermatol; 2014 Aug; 13(8):899-900. PubMed ID: 25116964
[No Abstract] [Full Text] [Related]
16. Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma.
Garuti F; Camelli V; Spinardi L; Bucci L; Trevisani F
Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27079903
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment.
Maksimovic O; Schraml C; Hartmann JT; Bitzer M; Claussen CD; Pintoffl J; Horger M
AJR Am J Roentgenol; 2010 Jan; 194(1):5-14. PubMed ID: 20028898
[TBL] [Abstract][Full Text] [Related]
18. Reproducible complete remission of advanced hepatocellular carcinoma with sorafenib in combination with clopidogrel.
Tan-Shalaby JL
BMJ Case Rep; 2014 Sep; 2014():. PubMed ID: 25178887
[TBL] [Abstract][Full Text] [Related]
19. Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience.
Kudo M; Ueshima K; Arizumi T
Dig Dis; 2012; 30(6):609-16. PubMed ID: 23258103
[TBL] [Abstract][Full Text] [Related]
20. Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study.
Daniele B; Croitoru A; Papandreou C; Bronowicki JP; Mathurin P; Serejo F; Stål P; Turnes J; Ratziu V; Bodoky G
Future Oncol; 2015 Sep; 11(18):2553-62. PubMed ID: 26158398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
